Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-12-15
2004-07-06
Caputa, Anthony C. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387700, C530S388260
Reexamination Certificate
active
06759204
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the field of cancer screening and monitoring.
BACKGROUND
A major problem in the treatment of cancer remains its early detection. Early detection enables therapeutic treatment from the onset of the disease resulting in successful treatment in many cases.
Numerous studies have demonstrated that tumour cells can express substances liable to be detected in blood and, as a result, liable to be used as tumour markers. It is possible to distinguish between two main types of such substances:
Substances related to tumour presence but which are not involved in tumour formation. Said substances include various proteins (mucins, CA 15-3 and CA 125 markers), protein fragments (cytokeratin fragments, CYFRA 21 marker), enzymes (neurospecific enolase, NSE marker), or oncofoetal antigens such as carcinoembryonic antigens and ACE markers. Such substances, present in normal cells, are altered by the tumoral activity and/or have access to the extracellular compartment due to tumoral necrosis. The detection of such substances is already widely used in clinical practice. However, they only appear when the tumour is established and, as a result, cannot be detected at an early stage.
Substances directly related to tumour formation. Such substances particularly include P53 protein which is produced by a tumour-suppressing gene, and is altered and/or overexpressed in tumours. This alteration and/or overexpression results in a modification of DNA repair control and a higher susceptibility of cells to cell transformation (see T. Soussi et al., 1994; Int. J. Cancer: 57, 1-9). Therefore, P53 protein alterations are the source of tumour formation, in which they represent an early stage. In addition, the presence of autoantibodies directed against P53 protein has been detected in the serum of patients suffering from cancer and the detection of said autoantibodies is under clinical study (C. P. Wild et al., 1995, Int. J. Cancer (Pred. Oncol.): 64, 176-181).
Therefore, substances directly related to tumour formation, such as P53 protein or autoantibodies directed against such protein represent effective cancer markers. However, in view of the increasingly rapid set-up of treatments, it is still necessary to identify new earlier markers. In addition, the markers already described, such as P53 protein, are characteristics of certain types of tumours and are, therefore, not sufficiently polyvalent to diagnose all types of cancer.
SUMMARY OF THE INVENTION
The invention relates to a diagnostic process for detecting cancer in a patient including identifying the presence of anti-Csk autoantibodies in a biological sample obtained from the patient. The invention also relates to a diagnostic kit for cancer diagnosis in a biological sample of a subject including Csk protein or a modified form, fragment(s) or conjugates of the substances, reagents to create a medium favorable to an immunological reaction between the Csk proteins or a modified form, fragment(s) or conjugates of the substances and the anti-Csk autoantibodies possibly present in the biological specimen, and one or more reagents which react with Csk proteins or a modified form, fragment(s) or conjugates of said substances and/or anti-Csk autoantibodies and/or immunological complexes, to detect immunological complexes possibly formed.
REFERENCES:
patent: 92 02187 (1995-01-01), None
patent: 95 24205 (1995-09-01), None
Cam WR, et al. Cancer 2001; 92: 61-70.*
Sakai et al (Lab Invest., Feb. 1998, vol. 78(2):219-25, abstract).*
Verbeek et al (J. Pathol., 1996, vol. 180(4):383-8, abstract).*
Iravani et al (Lab Invest., Mar. 1998, vol. 78(3):365-71, abstract).*
Tockman, MS, et al, 1992, Considerations in bringing a cancer biomarker to clinical application, Cancer Research, vol. 52, Suppl., pp. 2711s-2718s.*
Bjorge, JD, et al, 2000, Identification of protein-tyrosine phosphatase 1B as the major tyrosine phophatase activity capable of dephosporylating and activating c-src, Journal of Biological Chemistry, vol. 275, No. 52, pp. 41439-41446.*
Bougeret, C, et al, 1996, Detection of a physical and functional interaction between Csk and Lck which involves the SH2 domain of Csk and is mediated by autophosphorylation of Lck, Journal of Biological Chemistry, vol. 271, No. 13, pp. 7465-7472.*
Benistant, C, et al, 2001, THe COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma, Cancer Research, vol. 61, No. 4, pp. 1415-1420.*
Masaki, T, et al, 1999, Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma, Hepatology, vol. 29, No. 2, pp. 379-384.*
Montenarh, M, et al, 1998, p53 autoantibodies in the sera, cytst and ascitic fluids of patients with ovarian cancer, International Journal of Oncology, vol. 13, No. 3, pp. 605-610.*
Marx, D, et al, 2001, Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer, Cancer Detection and Prevention, vol. 25, No. 2, pp. 117-122.*
Moch, C, et al, 2001, Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies, British Journal of Cancer, vol. 85, No. 12, pp. 1883-1886.*
Broll, R, et al, 2001, p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue, Int. J. Colorectal Dis., vol. 16, No. 1, pp. 22-27.*
S. Zrihan-Licht et al., “Association of Csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErB-2 in breast cancer cells”. Journal of Biological Chemistry, vol. 272, No. 3, (Jan. 17, 1997) pp. 1856-1863.
M. Chedin et al., “Characterization of two different cytoplasmic protein tyrosine kinases from human breast cancer”. Chemical Abstracts, vol. 127, No. 18, (Nov. 3, 1997), Abstract No. 244619.
Bali Jean-Pierre
Benistant Christine
Bourgaux Jean-François
Chapuis Heliette
Mottet-Auselo Nicolas
Caputa Anthony C.
Centre National de la Recherche Scientifique--CNRS
Piper Rudnick LLP
Rawlings Stephen L.
LandOfFree
Method and kit for early diagnosis of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and kit for early diagnosis of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and kit for early diagnosis of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3231611